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Chronic pain represents a major public health problem worldwide. Current pharmacological treatments for chronic pain
syndromes, including neuropathic pain, are only partially effective, with significant pain relief achieved in 40–60% of patients.
Recent studies suggest that the mammalian target of rapamycin (mTOR) kinase and downstream effectors may be implicated in
the development of chronic inflammatory, neuropathic, and cancer pain. The expression and activity of mTOR have been detected
in peripheral and central regions involved in pain transmission. mTOR immunoreactivity was found in primary sensory axons, in
dorsal root ganglia (DRG), and in dorsal horn neurons. This kinase is a master regulator of protein synthesis, and it is critically
involved in the regulation of several neuronal functions, including the synaptic plasticity that is a major mechanism leading to the
development of chronic pain. Enhanced activation of this pathway is present in different experimental models of chronic pain.
Consistently, pharmacological inhibition of the kinase activity turned out to have significant antinociceptive effects in several
experimental models of inflammatory and neuropathic pain. We will review the main evidence from animal and human studies
supporting the hypothesis that mTOR may be a novel pharmacological target for the management of chronic pain.
1. Introduction
Chronic pain represents a major public health problem
worldwide, affecting approximately 37% of the US popula-
tion, with an economic burden of up to US$ 635 billion per
year [1]. In Europe, the prevalence of chronic pain syndromes
ranges between 25 and 30% [2]. Physiologically, nociceptive
pathways are activated in response to traumatic or noxious
stimuli. Acute pain, which is primarily due to nociception,
serves as an adaptive and protectivemechanism to detect, loc-
alize, and limit tissue damage; on the contrary, chronic pain,
which persists after a reasonable time for healing to occur
(ranging between 1 and 6 months in most definitions), can
be regarded as a form of maladaptive response, in which
pain is no longer protective or strictly linked to the initial
stimulus. After application of an intense and prolonged
injury, ongoing excitation of primary nociceptive neurons
leads to neuronal changes both in the primary afferents
(peripheral sensitization) and in the spinal dorsal horn neu-
rons (central sensitization), contributing to the development
of chronic pain [3]. In this condition, pain arises in the
absence of noxious stimulus, may be stimulated by normally
innocuous stimuli (allodynia), is exaggerated and prolonged
in response to noxious stimuli (primary hyperalgesia), and
spreads beyond the site of injury (secondary hyperalgesia)
[3]. Chronic pain has a neuropathic origin in approximately
20% of the patients [2]. Neuropathic pain may arise from a
direct damage of somatosensory nerves or nerves innervating
visceral organs or from a disease affecting the somatosensory
nervous system which implies an indirect injury resulting
fromvarious causes, includingmetabolic stress, autoimmune,
degenerative, or chronic inflammatory conditions, and idio-
pathic origins [4].
Neuropathic pain is characterized by pain hypersensitiv-
ity that is mediated by both peripheral and spinal neuronal
synaptic plasticity (leading toperipheral and central sensiti-
zation, resp.), involving pre- and posttranslational changes
in the expression and functions of receptors, enzymes, and
voltage-dependent ion channels in sensory neurons [3]. In
addition, other biochemical events contribute to the hyper-
activity of the somatosensory system, including phenotypic
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Figure 1: Schematic representing the molecular partners of mTOR forming (a) mTOR complex 1 (mTORC1) and (b) mTOR complex 2
(mTORC2). The down-arrows indicate the inhibitory proteins, whereas the up-arrows indicate activator factors on mTOR function.
neuronal switch (i.e., large myelinated A𝛽 fibers expressing
neuropeptides directly involved in pain transmission, such as
substance P and calcitonin gene-related peptide), sprouting
of nerve endings (i.e.,myelinatedA𝛽fibers establishing direct
contacts with nociceptive projecting neurons in the lamina I-
II of the spinal dorsal horn), loss of spinal inhibitory control,
and increased activity of descending excitatory pathways
[3]. Moreover, synaptic plasticity within key cortical regions
involved in pain processing (i.e., the anterior cingulated cor-
tex, the insular cortex, primary and secondary sensory cor-
tices, and the amygdala) has been also observed in relation
to neuropathic pain [4]. Finally, activation of glial cells with
release of pronociceptive mediators can directly modulate
neuronal excitability and thus pain transmission, contribut-
ing to central sensitization and to the occurrence of neuro-
pathic pain [5].
Multimodal pharmacological treatments for chronic pain
syndromes, including neuropathic pain, are based on the
use of antiepileptics, antidepressants, local anesthetics, opioid
analgesics, or tramadol. These treatments are only partially
effective, with significant pain relief achieved in 40–60% of
patients [4]. A relatively recent modality of neuropathic pain
therapy, which represents the future challenge of upcoming
researches, involves specific cellular targets implied in neu-
ronal synaptic plasticity and/or glial activation [6]. Inter-
estingly, recent studies show that the mammalian target of
rapamycin (mTOR) kinase and downstream effectors may be
implicated in the development of chronic inflammatory, neu-
ropathic, and cancer pain.This kinase is a master regulator of
protein synthesis, and it is critically involved in the regulation
of several neuronal functions, including synaptic plasticity
and memory formation in the central nervous system (CNS)
[7]. As mentioned above, neuronal synaptic plasticity both at
peripheral level and in the CNS is amajormechanism leading
to the development of chronic pain, thus suggesting that
mTOR may be a novel pharmacological target for the man-
agement of chronic pain. In addition, mTOR has been also
reported to regulate astrocyte and microglial activity (as we
have recently reviewed [8]), thus suggesting an additional
therapeutic target in the treatment of chronic pain syndromes
that involve increased glial activation. The main evidence
from animal studies as well as clinical reports supporting this
hypothesis is reviewed in the present paper.
2. mTOR, the ‘‘Mechanistic’’
Target of Rapamycin
The mTOR kinase, now officially known as “mechanistic”
TOR, is a conserved serine/threonine protein kinase belong-
ing to the phosphoinositide 3-kinase (PI3K) family that
regulates multiple intracellular processes [9]. In mammals,
mTOR is encoded by a single gene [10] and interacts with
several proteins to form two distinct complexes, referred to as
mTORC1 and mTORC2. These complexes display different
sensitivity to the inhibitory action of rapamycin, which
mainly suppresses mTORC1-dependent activities in acute
treatments [11]. Notably, the two complexes promote the acti-
vation of different signalling pathways and recognize distinct
upstream regulators as well as downstream targets, whose
specificity is determined by the specificity of the interacting
proteins. Both complexes include the inhibitory protein
DEPTOR and the adaptor protein mLST8/G𝛽L (mammalian
LST8/G-protein 𝛽-subunit like protein) [12]. However, the
role of mLST8/G𝛽L in the regulation of mTORC1 function
remains unclear at present, since its chronic loss does not
affect mTORC1 activity in vivo [13]. As shown in Figure 1,
mTORC1 specifically contains the regulatory-associated pro-
tein of mTOR (raptor) and the inhibitory protein PRAS40
(proline-richAKT substrate of 40KDa) [14]. Raptor regulates
mTORC1 assembly and serves as a scaffold for the recruit-
ment of specific substrates, such as the eukaryotic initiation
factor-4E-binding protein 1 (4E-BP1) [15, 16]. Similarly, other
proteins reside uniquely within complex 2, that is, the
rapamycin-insensitive companion ofmTOR (rictor), the pro-
tein observedwith rictor (PROTOR), and the stress-activated
protein kinase-interacting protein 1 (mSIN1) (Figure 1) [17].
Much like raptor, rictor is necessary for mTORC2 assembly
together with mSIN1, for mTORC2 catalytic activity, and it
may also be involved in the selective recruitment of specific
substrates [14].
BioMed Research International 3
Growth factors (i.e., insulin,
insulin-like growth factors)
4E-BP1
S6K1
eiF-4B
eiF-4E
mRNA translation 
eEF2 kinase
Protein elongation 
Cell growth and proliferationAutophagy
mRNA translation 
S6
Ribosomal biogenesis
Lysosomal
biogenesis
PKB/AKT
Energy metabolism
PI3K
IRS1
Cytokines 
Rheb
ERK1/2
Ras
Hypoxia
low cell ATP
AMPK
Aminoacid content
(ARG-LEU)
RAG A/B
mTORC1
TSC1 TSC2
Lysosomes
(TNF𝛼)
I𝜅BK
Figure 2: Schematic representing the main intracellular targets as well as the main cellular processes regulated by mTORC1.
The mTOR complex 1 is activated in response to different
intracellular and extracellular cues, that is, growth factors,
cytokines, energy status, oxygen, and amino acids, to control
multiple functions related to cell growth andmetabolism [12].
As shown in Figure 2, several upstream regulators of
mTORC1 activity converge on theheterodimer consisting of
tuberous sclerosis 1 (TSC1, also known as hamartin) and
TSC2 (also known as tuberin). In this complex, TSC1 stabi-
lizes TSC2 by preventing its degradation, while TSC2 acts as
aGTPase-activating protein (GAP) for the small GTPase pro-
tein, Rheb (Ras homolog enriched in brain) [18]. Rheb in its
GTP-bound state binds to and activates mTORC1, whereas
the TSC1/2 complex normally inhibits mTORC1 activity by
favoring the GDP-bound inactive state of Rheb. As recently
reviewed by Laplante and Sabatini [12], growth factors (such
as insulin and insulin-like growth factors) increase mTORC1
activity, by promoting the phosphorylation and degradation
of the TSC1/2 complex. This occurs via ligand-dependent
activation of receptor tyrosine kinases (RTKs), like the
insulin receptors, followed by activation of the PI3K and Ras
pathways.The effector kinases of these pathways, namely, the
protein kinase B (PKB/AKT) and the extracellular-signal-
regulated kinases (ERK) 1 and 2, induce TSC1/2 phosphoryla-
tion (Figure 2). In addition, AKT can directly phosphorylate
the inhibitory protein PRAS40, promoting its dissociation
from raptor and further contributing to mTORC1 activation.
Proinflammatory cytokines, like TNF𝛼, increase mTORC1
activity via I𝜅B kinase- (IKK-) dependent inactivation of the
TSC1/2 complex, whereas, in response to hypoxia or low
energy status, the adenosinemonophosphate activated kinase
(AMPK) blocks mTORC1 activity, by increasing TSC2
function and directly inhibiting raptor (Figure 2). Finally,
increased intracellular levels of aminoacids, particularly argi-
nine and leucine, promote mTORC1 activation, by inducing
its binding to a distinct family of GTPases, the Rag GTPases,
together with its translocation to the lysosomal surface [19,
20]. It has been hypothesized that translocation of mTORC1
to the lysosomes allows GTP-bound Rheb to interact with
mTORC1, promoting its activation only when aminoacids are
available. Additional details on the regulation ofmTORC1 can
be retrieved in the above mentioned review article [12].
Protein synthesis is the best-characterized intracellular
process regulated by mTORC1, whose activation generally
increases the cellular capacity of protein generation [14]. The
two main downstream targets of mTORC1, 4E-BP1 and the
ACG-family protein, S6 kinase 1 (S6K1), are key components
of the protein translation machinery. Phosphorylation of 4E-
BP1 causes its dissociation from the eukaryotic translation
initiation factor- (eIF-) 4E (Figure 2). This allows eIF-4E to
associate with eIF-4G leading to the formation of eIF-4F,
which facilitates the loading of ribosomes onto the mRNA.
By this molecular mechanism, mTORC1 can control the
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translation of specific mRNAs, including the so-called 5󸀠-
TOP mRNAs that mostly encode for components of the
translational machinery. In addition, phosphorylation and
activation of S6K1 promote protein translation by phosphory-
lation of several substrates, including eIF-4B, the eukaryotic
elongation factor 2 (eEF2) kinase, and the ribosomal S6
protein (Figure 2). Local protein synthesis within sensory
neurons contributes to their nociceptive functions both
under physiological conditions and during chronic pain. As
described in detail in Section 4, by controlling protein trans-
lation mTORC1 can regulate the activity of sensory neurons,
in periphery as well as in the CNS. The activity of S6K1 is
also important in the control of RTK activation. In fact, S6K1
(activated by mTORC1) promotes also the phosphorylation
and inactivation of IRS1, the insulin receptor substrate 1. The
latter is a docking protein that in its tyrosine-phosphorylated
form couples the insulin receptor to its downstream effectors
[21].This is part of a retroinhibitory feedbackmechanism that
reduceRTKactivation, thus the activity ofAKT andERK [12].
The latter is also a kinase critically involved in the regulation
of pain processing (see Section 4). The mTOR complex
1 is also involved in the regulation of several metabolic
pathways, regulating the expression of genes encoding dif-
ferent steps of glycolysis and the pentose phosphate pathway,
as well as critical enzymes in the de novo biosynthesis
of lipids [22]. Finally, mTORC1 can favor cell growth by
negatively regulating macroautophagy (autophagy), the cen-
tral degradative process in cells, and lysosome biogene-
sis [12, 14]. As discussed in detail in Section 4, the acti-
vation of autophagy in Schwann cells can limit the extent of
axonal degeneration after nerve injury and promote regener-
ation and myelination, thus favoring analgesic effects.
In contrast tomTORC1,mechanisms leading tomTORC2
activation are less characterized. It seems that mTORC2
activation is directly promoted by PI3K via phosphorylation
of specific mTORC2 interactors, including rictor (Figure 3)
[17]. Thus, mTORC2 appears to be also responsive to growth
factors, but insensitive to nutrients. mTORC2 regulates the
activity of several proteins belonging to the ACG family,
including AKT, the serum- and glucocorticoid-induced pro-
tein kinase (SGK1), and protein kinase C- (PKC-) 𝛼. AKT is a
key regulator of cell survival and proliferation, withmTORC2
promoting its phosphorylation at Ser
473
in the hydrophobic
motif and maximal activation [23, 24]. In this way, mTOR
appears to be both a downstream effector of AKT (i.e.,
mTORC1) and an important upstream regulator of the kinase
activity (i.e., mTORC2) (Figure 4). Moreover, it has been
shown that an intricate crosstalk exists between the two
complexes (Figure 4), since S6K can negatively control the
activation of mTORC2 [24], whereas TSC1/2 positively con-
tributes to mTORC2 activation [25]. The mTOR complex 2
also promotes the activity of SGK1, another important kinase
in the control of cell proliferation [26]. Finally, activation of
PKC𝛼 by mTORC2, along with other effectors (like paxillin
and Rho GTPases), regulates the dynamic of actin cytoskele-
ton [27, 28]. Direct regulation of AKT activity together with
a role in the control of actin dynamics suggests a possible
involvement of mTORC2 in the control of neuronal function,
as discussed in Section 4.
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Figure 3: Schematic representing the main intracellular targets as
well as the main cellular processes regulated by mTORC2.
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3. mTOR Inhibitors
The mTOR kinase, now officially known as “mechanistic”
TOR, was initially identified as “mammalian target of
rapamycin,” because the kinase is the main target of an anti-
fungal compound derived from Streptomyces hygroscopicus,
rapamycin [29]. This drug, discovered in soil samples col-
lected from Easter Island (Rapa Nui, from where the name),
was originally found to have antifungal proprieties, but
rapidly its immunosuppressive activity became its more
important property. Actually, rapamycin is widely used in
preventing clinical allograft rejection and in treating some
autoimmune diseases [30]. In the 1980s, rapamycin was also
found to have anticancer activity, although the exact mecha-
nism of action remained unknown until many years later.
Rapamycin (or sirolimus)mainly inhibitsmTORC1 activ-
ity by forming a trimolecular complex with mTOR and the
immunophilin, FKBP12 (FK506-binding protein of 12 kDa;
also known as PPIase FKBP1A). The drug associates with
FKBP12, and the resulting complex interacts with the FRB
(FKBP12-rapamycin binding) domain located in the carboxyl
terminus of mTOR: the interaction disrupts the association
with raptor and thus uncouples mTORC1 from its substrates
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inducing a block of mTORC1 signaling [31, 32]. However,
not all the functions mediated by mTORC1 are sensitive to
rapamycin; the inhibition of cap-dependent translation and
the induction of autophagy are in part resistant to rapamycin
[33]. Originally, the effects of rapamycin were thought to
be only related to the inhibition of mTORC1, but studies
of Sabatini’s group have shown that rapamycin given at
higher concentrations and in chronic treatments also inter-
feres with mTORC2 regulatory functions [11]. In particular,
high intracellular levels of rapamycin inhibit the binding
and subsequent assembly of mTORC2-specific components
mSIN1 and rictor [11].
Rapamycin readily crosses the blood brain barrier (BBB),
thus exerting direct effects within the CNS [34]. However, in
order to ameliorate the pharmacokinetic profile of rapamy-
cin, novel drugs have been developed.This first generation of
mTOR inhibitors displays the same binding sites for mTOR
and FKBP12 and is thus so-called rapalogs (i.e., rapamycin
and its analogs). Rapalogs includes CCI-779 (temsirolimus),
RAD-001 (everolimus), and AP23573 (ridaforolimus or
deforolimus) (Table 1). Among these mTOR inhibitors, CCI-
779 is a prodrug of rapamycin, which delays tumor pro-
liferation [35], and it is actually used for the treatment of renal
cell carcinoma, whereas RAD-001, a 40-O-(2-hydroxyethyl)
derivative of rapamycin, is currently used as an immuno-
suppressant to prevent rejection of organ transplants and,
like CCI-779, for the treatment of renal cell cancer and
subependymal giant cell astrocytoma [36].
However, the use of rapalogs unmasked the feedback loop
between mTORC1 and AKT in certain type of cells. The
mTORC1 inhibition induced by these drugs fails to repress
the negative feedback loop that results in phosphorylation
and activation of AKT, and it is unable to block the mTORC2
positive feedback to AKT [37]. The elevation of AKT activity
can promote a longer survival in some cell types and may
also be associated to pain hypersensitivity (as described in
Section 4).These limitations have led to the development of a
second generation of mTOR inhibitors: the ATP-competitive
mTOR inhibitors, which block both mTORC1 and mTORC2
activity [38]. Unlike rapamycin, which is a specific allosteric
inhibitor of mTORC1, these ATP-competitive inhibitors tar-
get the catalytic site of the enzyme, thus promoting a broader,
more potent, and sustained inhibition of mTOR and prevent-
ing the activation of PI3K/AKT caused by the derepression of
negative feedbacks [39]. This is due to the effective inhibition
of rapamycin-insensitive mTORC2 activity in addition to
mTORC1 inhibition and also to a more comprehensive and
sustained mTORC1 inhibition as demonstrated by sustained
reduction of 4E-BP1 phosphorylation [38]. Actually, many
compounds with different chemical structures show these
functions (see Table 1) and some of them are being tested in
clinical trials.
Finally, the close interaction of mTOR with the PI3K
pathway has also led to the development of mTOR/PI3K
dual inhibitors [40]. Compared with drugs that inhibit either
mTORC1 or PI3K, these drugs have the benefit of inhibiting
both mTORC1 and mTORC2 and all the catalytic isoforms of
PI3K. Interestingly, because of the high sequence homology
between mTOR and PI3K, some compounds (like wortman-
nin), originally identified as PI3K inhibitors, were later shown
to inhibit mTOR as well [41]. The activity of these small
molecules differs from rapalog activity, for a more specific
block of both mTORC1-dependent phosphorylation of S6K1
and mTORC2-dependent phosphorylation of AKT at the
Ser
473
residue. Dual mTOR/PI3K inhibitors include NVP-
BEZ235, BGT226, SF1126, and PKI-587 (Table 1), and many
of them are being tested in early-stage of preclinical trials.
A detailed list of mTOR inhibitor drugs is provided
in Table 1, together with specific information on their
molecular properties (including in vitro mTOR IC50 and
cellular potency towards mTORC1 and mTORC2). Dual
mTORC1/mTORC2 inhibitors have been developed by coun-
terscreening their inhibitory activity against the most closely
related kinases, class I and class III PI3K lipid kinases and the
PI3K-related kinase (PIKK) family members [42], whereas
dual PI3K/mTORC inhibitors were optimized to inhibit class
I PI3Ks [43].Thus, the in vitro inhibitory potency against class
I PI3Ks has been also included in Table 1. As far as the ATP-
competitive mTOR inhibitors (first generation and second
generation) are concerned, we calculated the ratio between
PI3K and mTOR IC50 and marked those drugs with a ratio
<500 since inhibition of PI3K by these drugs may become
relevant in cellular or in vivo systems. This information
should provide the reader with a better understanding of the
biological effects of these novel drugs.
4. mTOR in the Control of Chronic Pain
4.1. Histology. The expression and activity of mTOR have
been extensively detected in peripheral and in central regions
involved in pain transmission, both under physiological con-
ditions and in several experimental models of inflammatory
and neuropathic pain. In the adult rat and mouse cutaneous
tissue, mTOR immunoreactivity was found in a subset of
primary sensory axons and in nonneuronal cells surrounding
the peripheral axons in the dermis [44, 45]. Using specific
markers that distinguish between C- and A-fibers, it has been
shown that mTOR positive axons are mainly myelinated A-
fibers, and only less than 5% are peptidergic fibers, coexpress-
ing CGRP. Interestingly, these fibers were stained also for the
active form of mTOR, evaluated by measurement of mTOR
phosphorylation at Ser
2448
. This phosphorylation primarily
reflects a feedback signal from the mTORC1 downstream
target S6K1 (also known as p70S6 kinase, p70S6K), and it is
therefore considered a reliable marker of mTORC1 activation
within the cells [46]. Moreover, myelinated sensory fibers in
the rat skin also express phosphorylated downstream targets
of mTORC1, including 4E-BP1, S6K, and the S6 ribosomal
protein [44], suggesting that mTORC1 may regulate local
protein synthesis within these axons thus contributing to
their nociceptive functions under physiological conditions.
These fibers, particularly the large A-beta (A𝛽) fibers, are
normally involved in the conduction of nonnociceptive
inputs such as light touch,movement, or vibration [47]. How-
ever, amplification of their signals by sensitized dorsal horn
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Table 1: mTOR inhibitor drugs.
Classes Drugs
mTOR
(in vitro kinase
IC50)
mTORC1
(cellular potency
EC50)
mTORC2
(cellular
potency EC50)
Class I PI3K
(in vitro kinase
IC50)
References
Rapamycin
1.74𝜇M
(2 nM1, in presence
of FKBP12)
0.4–3.5 nM2 [82–84]
Rapalogs
RAD001 0.4–3.5 nM2 [82]
CCI-779 1.76 𝜇M <20 nM 10–20𝜇M [84]
AP23573 0.2 nM [85]
ATP-competitive
mTOR inhibitors
(first generation)
KU-0063794 2.5 nM1 660 nM3 240 nM3 >5.3–>30 𝜇M [86–88]
PP2424 8 nM 300–400 nM 0.10–2.2 𝜇M [89, 90]
PP304 80 nM 0.68–5.8𝜇M [89]
Torin 14 4.3 nM 2–10 nM 2–10 nM 0.17–>10𝜇M [90, 91]
WEY-6004 9 nM1 300 nM 1 𝜇M 1.96–8.45 𝜇M [92]
WYE-3544 5 nM1 300 nM 1 𝜇M 1.89–7.37 𝜇M [92]
CC214-1 2 nM 40 nM 18 nM 1.38 𝜇M [93]
OSI-0274 4 nM 0.42–>30 𝜇M [94]
X-3874 23 nM1 0.12–>0.3 𝜇M [95]
ATP-competitive
mTOR inhibitors
(second generation)
AZ8055 0.13 nM1 27 nM3 24 nM3 3.2–18.9 𝜇M [42, 88]
AZ2014 2.8 nM1 200 nM3 80 nM3 3.8–>30 𝜇M [88]
INK128/MLN01284 1 nM <10 nM <10 nM 0.22–5.29 𝜇M [96]
WYE-125132 0.19 nM1 20 nM 200 nM 1.18–>10𝜇M [97]
CC214-2 106 nM 386 nM 315 nM >30 𝜇M [93]
ATP-competitive
mTOR/PI3K dual
inhibitors
Wortmannin 0.2 𝜇M1 0.1 nM [83, 98]
LY294002/SF11015 1.5𝜇M1 0.5–1.6 𝜇M [83, 99–101]
PI-1035 In vitro kinaseIC50: 20 nM
In vitro kinase
IC50: 83 nM 2–15 nM [40, 100, 101]
Torin 2 2.81 nM 0.25 nM 10 nM 4.68–17.5 nM [102, 103]
GSK2126458 ND Low nM 0.18–0.41 nM 0.04 nM [104]
NVP-BEZ2355 20.7 nM <250 nM 8nM 4–75 nM [43, 101]
NVP-BGT2266 4–63 nM [105]
SF1126 (RDGS
conjugated SF1101)
Not significant
inhibitory activity
until hydrolyzed to
SF1101
[106]
PKI587 1.4 nM1 <30 nM <10 nM 0.6–8 nM [107]
In vitromTOR kinase IC50 was evaluated using either the immunoprecipitated or the recombinant full length enzyme. Cellular potency for the two different
mTOR complexes was calculated after short term incubation, ranging between 30min and 2 h, of different cell lines with mTOR inhibitors and subsequent
analysis of the phosphorylation status of specific mTORC1 (S6K or S6) or mTORC2 (AKT, at Ser
473
) substrates. In vitro PI3K and PIKK IC50 were measured
using specific biochemical assays.
1A truncated mTOR enzyme was used in the in vitro kinase assay.
2Cellular potency was evaluated by inhibition of cell proliferation, using vascular smooth muscle cells stimulated by fetal calf serum.
3Cellular potency was evaluated using a high throughput immunocytochemical assay, carried out in the MDA-MB-468 cell line.
4Ratio between PI3K and mTOR IC50 is <500.
5The reader should also consider IC50 values reported by Hayakawa et al., 2007 [99], and Kong et al., 2009 [101].
6NVP-226 is considered a dual mTOR/PI3K inhibitor. However, in vitro preclinical data on the mTOR inhibitory activity for this compound were not found
through Medline Search.
neurons is thought to account for secondary hyperalgesia and
allodynia, clinical features of chronic pain (as summarized in
Section 1). Consistently, active mTORC1 and its downstream
phosphorylated targets (4E-BP1 and the S6 ribosomal pro-
tein) have been also detected in the adult rat dorsal roots,
mostly in myelinated axons [48]. Local or intrathecal admin-
istration of rapamycin significantly reduced phosphorylation
of downstream targets of mTORC1 both in the peripheral
fibers [44] and in the central spinal cord neurons [48].
Similarly to these data, phospho-mTOR was also found to be
expressed by a subset of myelinated fibers in the adult mouse
dorsal roots [45], whereas, in rat dorsal root ganglia (DRG),
positive immunoreactivity for mTOR and S6K1 was detected
mainly in the cell body of small nociceptors, coexpressing
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substance P or IB4 positive [49]. These data suggest that
mTOR and its downstream targets are mostly transported to
myelinated peripheral and central fibers in the medium and
large (but not small) DRG neurons [44, 48]. In addition, at
the DRG level, a predominant expression of 4E-BP1 has been
detected in GFAP positive satellite cells [49]. Satellite cells are
specialized glial cells that surround the cell body of sensory
neurons both in DRG and in trigeminal ganglia and, like
central glia, are involved in the development of chronic pain
[50]. Studies from our laboratory have shown that satellite
glial cells contribute to neuronal sensitization of trigeminal
neurons in vitro [51] and that they can express functional
CGRP receptors which increase the stimulatory effects of
cytokines [52]. Finally, Xu et al. [49] have documented the
expression ofmTOR andmTORC1 downstream targets in the
dorsal horn of rat spinal cord.However, these authors failed
to detect the phosphorylated proteins both at the DRG and
spinal cord level. On the other hand, Ge´ranton et al. [48],
using a tyramide signal amplification- (TSA-) enhanced
immunofluorescent staining, demonstrated that phospho-
mTOR, phospho-S6 ribosomal protein, and phospho-4E-BP1
are strongly expressed in lamina I/III projection neurons of
the dorsal horn, that is, those neurons critically involved in
the development and maintenance of chronic pain [53].
Consistently with a possible involvement of mTOR in
chronic pain processes, it has been shown that peripheral
inflammation increases mTOR activation in the spinal cord
dorsal horn. In particular, intraplantar injection of capsaicin
significantly increased the phosphorylation level of the S6
ribosomal protein after 2 h in the dorsal horn neurons, an
effect abolished by intrathecal administration of rapamycin
[48]. Intraplantar injection of carrageenan increased the
magnitude of S6 phosphorylation in the ipsilateral spinal
cord dorsal horn but not in the contralateral one, 4 h after
treatment. In these animals, phospho-S6 together with Rheb,
the positive regulator of mTOR activity, was mainly detected
in neurons, but not in spinal glia (astrocytes and microglia).
Moreover, basal S6 activity was also detected in larger motor
neurons in the ventral horn, but it was not modified by
carrageenan peripheral administration [54]. Finally, periph-
eral inflammation due to intraplantar injection of complete
Freund’s adjuvant significantly increased mTOR activation
in DRG neurons, with a minor increase observed in spinal
cord dorsal horn [55]. Enhanced activation of the mTOR
pathway was also found in different experimental models of
neuropathic pain. In adult male rat undergoing L5-L6 spinal
nerve ligation (SNL), increased phospho-mTOR staining was
detected in sensory neurons mainly in myelinated fibers of
injured nerves [56]. However, Asante et al. [57] in the same
model measured reduced levels of CGRP and S6K1 in the
superficial dorsal horn neurons, just at the ligated L5-L6
nerves, but not in the uninjured L4 spinal cord. Increased
mTOR activation was instead found in a mouse model of
chronic crush injury (CCI) at the spinal cord level, and it
was significantly reduced by intrathecal administration of
rapamycin. In particular, rapamycin reduced phospho-
mTOR expression at 7 and 14 days after surgery, together with
significant reduction of the phosphorylation level of S6K1 and
4E-BP1 at 7 (but not 14) days after surgery [58]. In contrast, no
differences in the level of mTOR activation were detected in
the spinal cord dorsal horn 7 days after surgery, in a different
model of neuropathic pain induced by spared nerve injury
(SNI) of the sciatic nerve [48]. All together these data suggest
that mTORC1 activity is significantly elevated in dorsal horn
neurons in different models of chronic pain (even tough not
in all models), thus suggesting a possible involvement in
mediating central neuronal plasticity and thus pain hypersen-
sitivity. In support of this hypothesis, a recent paper by Xu
et al. [59] has demonstrated increased mTORC1 activation in
the spinal cord dorsal horn (at the lumbar level, but not at
cervical and thoracic level) in a rat model of morphine
induced tolerance and hyperalgesia, thus suggesting that the
reduced analgesic effects of morphine observed in long-term
treatments may be due to the upregulation of mTORC1
activity within the spinal cord. It is, therefore, possible that
inhibition of mTORC1 activity may have beneficial effects in
chronic pain syndromes.
4.2. Electrophysiology. In addition to these data, there is
also consistent electrophysiological evidence which point
out mTOR signaling pathways as important modulators of
chronic pain [44, 57, 60]. The electrophysiological analysis
conducted by Jime´nez-Dı´az et al. [44] revealed an increased
mechanical threshold of subsets of myelinated fibers, the A-
fiber nociceptors, after intraplantar injection of rapamycin,
following capsaicin induced injury in rats. The authors
proposed that ongoing local protein synthesis is essential for
the complete response of this subset of nociceptors and were
pioneers in supposing the possibility that a similar process is
operating at the sites of termination of sensory afferents
within the dorsal horn [44]. The role of mTOR in the neuron
injury-induced hyperexcitability was demonstrated later in a
study conducted by Asante et al., in which rapamycin (50𝜇L
of 250 nM), directly applied on the spinal cord at L4-L5
level, was found to produce inhibitory effects on nociceptive
C-fiber activity in lamina V wide dynamic range (WDR)
neurons, in response to mechanically and thermally stimulus
in rats after removal of lumbar vertebral segments L1–L3 of
the spinal cord [60]. For the thermally induced response, a
significant inhibition was only found at 35∘C, with a trend
towards reduction at higher temperatures. Also formalin-
induced hyperexcitability was attenuated by spinally admin-
istered rapamycin, with significant effects only in the second
phase of formalin test, which is thought to be due to
central sensitization of dorsal horn neurons as a result of the
initial attenuation of input from nociceptive C-fiber afferents
occurring during the first phase. The same authors demon-
strated similar effects of anisomycin, a general inhibitor of
protein translation, on the formalin test, confirming that
these effects were indeed due to inhibition of mRNA trans-
lation [60]. In a second paper, Asante et al. demonstrated
the spinal effects of the rapamycin analogue CCI-779 on
neuronal responses by using in vivo single-unit extracellular
recordings from spinal cord neurons of rats following L5-L6
SNL [57]. The authors found that spinal administration of
250 𝜇M CCI-779 significantly attenuated specific neuronal
responses to mechanical stimuli from SNL rats compared
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to predrug responses and sham rats, whereas no effect was
established on thermally evoked responses. In particular,
CCI-779 inhibitedC-fiber-mediated transmission ontoWDR
neurons. A further significant inhibitory effect was seen
on WDR neuronal postdischarge and on “wind-up” phe-
nomenon, a potentiated response mediated by nociceptive
C-fibers activity and a measure of central hypersensitivity
mechanisms. The limitation of this study is represented by
the fact that no differences in electrophysiological responses
were found between sham and neuropathic rats before drug
injection. The authors stated that the increased excitability
of L4 WDR neurons in neuropathic rats could have masked
the adjacent L5 ligation, according to a previous study in
which periphery connected spinal neurons were shown to
expand their receptive fields after the samenerve ligation [61].
The observation that CCI-779 was quite ineffective on neu-
ronal responses in the absence of nerve injury [57] allows to
confirm that mTOR signaling at the spinal level is an integral
element of nociception and that its role in central sensitiza-
tion likely contributes to the persistence of pain.
4.3. Behavioral Studies. The antinociceptive effects of rapam-
ycin and its analogous CCI-779 (thus mTOR inhibition)
have been documented in several experimental models of
inflammatory and neuropathic pain. Using the formalin
test, it has been shown that rapamycin (administered both
intrathecally or locally in the paw) significantly reduced the
second phase of behavioral pain in mice [62]. Similarly, in
adult rats, intrathecal administration of rapamycin produced
a significant inhibition of formalin-induced second phase
flinches [63]. The formalin test is a well-characterized behav-
ioral model of chemically induced pain consisting of two
consecutive pain behavior phases, of which the second one
has been suggested to involve central sensitization of the noci-
ceptive system [64], thus suggesting an involvement of spinal
mTOR in inflammation induced hyperalgesia. On the other
hand, rapamycin, injected directly through the skin at L5-
L6 spinal cord level 30 minutes before the formalin test, was
shown to significantly reduce both pain behavioral phases
of the formalin test in adult rats, indicating an involvement
of mTOR in peripheral sensitization as well [60]. A possible
role of mTOR kinase (and thus local protein translation)
in mediating both peripheral and central neuronal sensiti-
zation is also suggested by other studies based on different
models of inflammatory pain. Inflammatory pain can be
induced by intradermal injection of other nociceptive and
algogenic substances including capsaicin, carrageenan, and
the complete Freund’s adjuvant (CFA) [64]. For example, the
injection of capsaicin produces both peripheral sensitization
of C- and A𝛿-nociceptors and central sensitization of dorsal
horn neurons [48]. The hallmark of peripheral sensitization
is represented by increased thermal sensitivity, most likely
supported by ERK activation in the cell body of nociceptors
followed by synthesis of TRPV1 receptors and their transport
to the axon terminals in the inflamed cutaneous tissue,
whereas increased mechanical sensitivity is mainly due to
central sensitization of spinal cord neurons [65]. In this
experimental model (in adult rats), rapamycin administered
either centrally or locally significantly reduced mechanical
hyperalgesia without affecting thermal hypersensitivity in
adult rats [44, 48]. In a similar manner, local and central
injection of CCI-779 reduced mechanical hyperalgesia, but
not thermal hypersensitivity developing in response to intra-
dermal injection of carrageenan in adult mice [45]. The
mechanical hypersensitivity that occurs in the undamaged
area surrounding the site of injury, in these models, is
known to be mostly transmitted by A-fibers and amplified by
sensitized dorsal horn neurons.
In this regard, electromyographic studies have shown that
both local and intrathecal injection of rapamycin significantly
increased threshold temperatures for paw withdrawal evoked
by fast heat ramps (activating A-fiber nociceptors) compared
to control injections of vehicle, thus suggesting a direct effect
on this subset of myelinated nociceptors known to be impor-
tant for the increased mechanical sensitivity that follows
injury [44, 48]. However, intrathecal injections of rapamycin
inhibited the activation of downstream targets of mTOR in
dorsal horn and dorsal roots, thus suggesting a modulatory
effect on both primary afferents and central neurons [48].
Consistently with these observations, centrally administered
rapamycin was shown to reduce mechanical allodynia in sev-
eral models of inflammatory pain [54, 55, 59]. However, these
studies reported variable effects on thermal sensitivity, with
inhibitory effects observed after intraplantar injections of
carrageenan [54, 63], and minor albeit significant reductions
of thermal hyperalgesia induced by intraplantar injection of
CFA [55]. Considering that the expression of mTOR and
other components of the translational machinery has not
been detected inC-nociceptors, these results further suggest a
direct role of spinal mTOR in the modulation of central pain
processing. Interestingly, the PI3K inhibitor, wortmannin,
was more effective at reducing pain hypersensitivity in
response to carrageenan, thus suggesting the involvement of
other pathways (including ERK) in the development of
central sensitization [63]. Moreover, intradermal injection of
carrageenan increased the phosphorylation level of AKT at
Ser
473
in the dorsal horn of spinal cord thus suggesting a con-
comitant activation ofmTORC2 in parallel with development
of hyperalgesia in response to peripheral inflammation [63].
Therefore, wortmannin by inhibiting PI3K can simultane-
ously affect both mTOR complexes and other signaling
pathways (including ERK; as described in Sections 2 and 3)
potentially important in mediating peripheral and central
sensitization thus resulting more effective than rapamycin in
chronic pain.
mTOR inhibitors also display beneficial effects in several
models of neuropathic pain, which are also characterized
by the development of secondary hyperalgesia. In summary,
intraplantar or intrathecal administration of rapamycin sig-
nificantly reducedmechanical allodynia developing after SNI
in rats [44, 48]. This model consists in a tightly ligation fol-
lowed by distal sectioning of the common peroneal and tibial
branches of the sciatic nerve, with preservation of the sural
nerve. It is characterized by increased mechanical sensitivity
observed 6 days after surgery in the spared sural territory, that
is, the lateral part of the hind paw [44, 48]. Similarly in
mice, intraplantar or intraperitoneal injection of CCI-779
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significantly reduced mechanical allodynia observed in the
lateral part of the hind paw three days after surgery [45].
Interestingly, in this study, the authors also evaluated the
effect of repeated administration of CCI-779 (4 injections
every 24 hours) observing a persistent reduction in mechan-
ical allodynia which was gradually lost 48 hours after the last
administration [45]. Moreover, in agreement with a possible
role of mTORC2 in mediating central neuronal plasticity, the
dual mTOR inhibitor Torin 1 appeared to be more effective
than rapamycin in this experimental model, either after
one injection or after repeated administrations [45]. Interest-
ingly, daily administration of metformin (which also inhibits
mTOR by promoting AMPK activation (see Section 2))
reduced mechanical allodynia in a mouse model of SNI [56].
In addition to these data, mTOR inhibitors were found to
exert beneficial effects in other models of neuropathic pain.
For example, CCI-779 or metformin significantly reduced
mechanical allodynia in a model of persistent pain caused by
SNL [56, 57], and rapamycin reduced mechanical hypersen-
sitivity in mouse models of CCI [58, 66]. In agreement with
these observations, Cui et al. have shown, using adult female
Sprague Dawley, which chronic (14 days) intrathecal admin-
istration of rapamycin reduced both the mechanical allody-
nia and the thermal hypersensitivity induced by CCI [67].
However, variable effects of rapamycin on thermal sensitivity
have been reported in this experimental model as well [58],
suggesting a main role of mTOR in the regulation of central
sensitization. Notably, peripheral nerve injury can induce a
different spectrum of glial (both microglia and astrocytes)
activation in the dorsal horn of the spinal cord. These cells
can release inflammatory and pronociceptive mediators, thus
significantly contributing to neuronal sensitization and to
the establishment of chronic pain syndromes [5]. Recent
experimental evidence from our group and others suggest a
direct role of mTOR in the regulation of glial inflammatory
responses and a potential beneficial role of rapamycin in
neuroinflammatory based diseases [8], including chronic
pain syndromes. In fact, rapamycin (centrally administered)
reduced CCI induced astrogliosis [67] but did not mod-
ify microglial activation when injected peripherally in the
affected hind paw [66]. These data suggest that rapamycin
may have multiple cellular and molecular targets that can
contribute to the therapeutic effects observed in vivo. In this
regard, Marinelli et al. have demonstrated the critical role of
autophagy, particularly in Schwann cells (SCs), in reducing
neuronal damage, clearing myelin debris, and facilitating
neuronal regeneration after injury [66]. In these animals,
rapamycin significantly increased the autophagic flux in SCs,
their proliferation, and improved myelination in injured
nerves [66]. Consistently, rapamycin improved myelination
in explant cultures from neuropathic mice by activating
autophagic mechanisms [68]. However, mice lacking mTOR
in SCs display hypomyelinated sciatic nerves [69], further
underlying the relevance of the mTOR pathway in the
regulation of myelination in both peripheral and central
nervous system [70, 71].
In this field, recent evidence from our group suggests that
mTOR inhibitors can reduce signs of neuropathic pain in a
chronic model of a demyelinating disease, the experimental
autoimmune encephalomyelitis (EAE). We have shown that
chronic administration of rapamycin was able to increase the
sensitivity threshold for mechanical allodynia, which is usu-
ally reduced at the clinical onset of disease [72]. In this study,
we observed that rapamycin ameliorates clinical andhistolog-
ical signs of EAE when administered to already ill animals, at
the peak of disease (therapeutic approach). Interestingly, the
histological study of the brains at the end of the experiment
revealed a significant improvement in the myelination of the
corpus callosum in the rapamycin treated animals, which
may be the consequence of reduced neuroinflammation
as well as a direct effect of rapamycin [72]. In addition,
rapamycin was also found beneficial in a mouse model
of cancer metastatic pain. In fact, repeated treatment with
rapamycin reduced both thermal and mechanical hyper-
sensitivity developing in response to intratibial injection of
prostate cancer cells. In this model of chronic cancer pain,
rapamycin was also effective when administered in a ther-
apeutic manner, that is, once daily 5 days after injection of
cancer cells within the tibia [73]. Rapamycinwas also effective
in a similar model of metastatic cancer pain induced by
intratibial inoculation of breast cancer cells [74]. Finally,
rapamycin reduced hyperalgesia associated with chronic
administration of morphine in rats [59], thus further sup-
porting a potential clinical use of mTOR inhibitors in the
management of chronic pain syndromes.
4.4. Preclinical and Clinical Evidence of a Pronociceptive Role
for mTOR Inhibitors. Despite the promising results from the
preclinical studies reviewed above, the role of rapamycin
and rapalogs in the clinical treatment of chronic pain is
undermined by the clinical evidence that chronic treatment
of patients with these mTORC1 inhibitors is associated with
increases in the incidence of pain [75, 76], including the possi-
ble development of complex regional pain syndrome (CRPS)
[77]. In addition, the anticancer agents, RAD001 or AP23573,
are associated with a number of unique toxicities, with one
of the most significant being the so-called painful mTOR
inhibitor-associated stomatitis (mIAS) [78]. However, mech-
anistic data are lacking concerningwhether and how rapalogs
are linked to the development of pain in patients chronically
treated with these drugs; hence more and appropriate clinical
studies are necessary to clarify this important issue. In this
regard, the only preclinical study carried out in C57bl/6 mice
that show possible negative effects of long-term mTOR inhi-
bition with respect to pain hypersensitivity is a recent paper
from Melemedjian et al. [79]. These authors demonstrated
that chronic rapamycin treatment (intraperitoneally injected
for 9 days) induced mechanical allodynia in sham-operated
animals, while reducing mechanical hypersensitivity in SNL
animals in agreement with data reviewed in Section 4.3.
Similarly, rapamycin partially reversed mechanical allodynia
in mice with SNI, while producing mechanical allodynia
in sham animals. Chronic administration of rapamycin
appeared to increase ERK andAKT phosphorylation in sham
animal sciatic nerves, thus suggesting that the abrogation of
the negative feedback loops on these other pathways due to
the incomplete blocking of mTORC1 (see Sections 2 and 3)
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may cause activation of other signaling pathways responsible
for pain development [79]. For example, increased ERK
activity can induce sensory neuron sensitization, mechanical
hypersensitivity, and spontaneous pain. Interestingly, the
clinically available antidiabetic drugmetformin, which is also
a AMPK activator thus mTOR inhibitor (see above), prevents
rapamycin-induced ERK activation and the development
of mechanical hypersensitivity and spontaneous pain [79].
These data suggest that a more complete inhibition of the
mTOR pathway can overcome these side effects of rapamycin
and its analogs. In this regard, in a retrospective study
conducted on diabetic patients, the use of metformin has
been found significantly associated with reduction of pain
symptoms in patients affected by lumbar radiculopathy, a
very frequent form of chronic pain syndrome [80, 81].
5. Conclusions
Data presented in this review paper strongly suggest that
mTOR has a critical role in several mechanism of pain
processing, including a role in the development of chronic
pain. However, clinical evidence suggests that chronic use
of first generation mTOR inhibitors may be associated with
development of pain hypersensitivity, thus underlying the
involvement of other signaling pathways including PI3K
downstream effectors (ERK, AKT, and more interestingly
mTORC2). A more comprehensive understanding of these
signaling pathways may lead to improved treatments for the
management of chronic pain. A vast array of novel inhibitors,
with a broader range of activity, is becoming available for
clinical testing. These have been mostly developed for cancer
treatment, but may also be employed in the management of
chronic pain.
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